Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
The funding round is led by Kalaari Capital. Aflac Ventures, Digital Horizon, Stride Ventures, and existing investors also participated in the round
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Crosscope Dx is a workflow integrated vendor-agnostic digital pathology platform that offers end-to-end digital pathology solutions with advanced workflow features
Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through innovative new products
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Subscribe To Our Newsletter & Stay Updated
